During the quarter ended March 31, 2026, certain of our directors and officers of the Company adopted a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in item 408(a) of Regulation S-K.
Stephen Vessey, Director of the Company, adopted a Rule 10b5-1 trading plan effective March 4, 2026. Mr. Vessey’s trading plan provides for the sale of up to 10,396 shares of common stock between June 3, 2026 and February 26, 2027, which is the expiration date of the plan.
ITEM 6. EXHIBITS
EXHIBIT INDEX
TO
FORM 10-Q
BIO-TECHNE CORPORATION
| | | | | |
|---|
| Exhibit Number | | | | Description |
| | | | | |
| 3.1 | | | | Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's 8-K dated November 1, 2022* |
| | | | |
| 3.2 | | | | Fourth Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated April 27, 2022* |
| | | | | |
| 10.1 | | | | Executive Employment Agreement—incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K dated February 11, 2026* |
| | | | | |
| 10.2 | | | | Executive Transition Agreement, dated March 1, 2026, between the Company and Dr. Matt McManus |
| | | | | |
| | | | | |
| 31.1 | | | Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| | | | |
| 31.2 | | | Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| | | | |
| 32.1 | | | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| | | | |
| 32.2 | | | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| | | | |
| 101 | | | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter and nine months ended March 31, 2026, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, (iv) the Condensed Consolidated Statements of Stockholders Equity, and (v) Notes to the Condensed Consolidated Financial Statements. | |
| | | | |
| 104 | | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
|---|
| | | BIO-TECHNE CORPORATION |
| | | (Company) |
| | | |
| Date: May 6, 2026 | | /s/ Kim Kelderman |
| | | Kim Kelderman |
| | | President and Chief Executive Officer |
| | | |
| Date: May 6, 2026 | | /s/ James Hippel |
| | | James Hippel |
| | | Executive Vice President, Chief Financial Officer |
filings.tools